2019 Prioritisation Report

Prioritisation of HIV, Hepatitis C and Tuberculosis medicines for in-licensing by the Medicines Patent Pool.
Comments are welcome and encouraged. Please send an email to info@medicinespatentpool.org with subject line “Comments on the 2019 Prioritisation Report”.

Access the 2019 Prioritisation Report

Access previous reports (archives)

MPP focuses on increasing access to HIV, hepatitis C and tuberculosis medicines. The organisation’s current remit also includes patented essential medicines with high medical value, with a priority given to small molecules, and those with strong potential for future inclusion on the World Health Organization Model List of Essential Medicines (EML).
Read more about our commitment to Universal Health Coverage and Essential Medicines.

Since our creation in 2010, we have published a list of priority HIV treatments for our licensing programme. In 2017, we expanded our evaluation to include important treatments for hepatitis C, and in 2018 we included tuberculosis treatments in our prioritisation work. Our method for prioritising HIV, hepatitis C and tuberculosis treatments, developed with the support of a broad range of experts, is based on four criteria:

  • The medicine’s clinical importance
  • The extent to which the treatment is patented in developing countries
  • Existing licensing agreements in place
  • The potential for market uptake.

In 2019, MPP published a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.

Target medicines may include those already in the market as well as investigational candidates. The focus is on medicines that are not yet licensed to MPP.


The 2019 Prioritisation Report includes one HIV and one TB compounds that could improve standard of care for people living in developing countries. It also includes three HIV and three TB compounds in watchlists.

Current target products and formulations:

HIV prioritisation
Cabotegravir long-acting injectable


TB prioritisation


In addition, the following products have been included in MPP watchlists:

HIV watchlist
Islatravir (MK-8591, EFdA)
GSK2838232 (GSK’232)
GS-6207 (GS-CA2)


TB watchlist
Telacebec (Q203)
Delpazolid (LCB01-0371)


Finally, the following three products have been identified as ARVs to be further monitored:

Other HIV products to monitor
Rilpivirine long-acting injectable


The MPP signed a licensing agreement with Pfizer in October 2019 to facilitate the clinical development of sutezolid, an investigational medicine for the treatment of tuberculosis (TB). Read more

The status of negotiations on priority products will be updated on a quarterly basis in line with MPP’s Transparency Policy.

This website uses cookies to ensure you get the best experience on our website. Learn More